Movement Alert｜Charles River Laboratories Intraday Rise 5.24% in Regular Trading, Analyst Target Hikes Support Sentiment

Market Focus10-21

On October 21, Charles River Laboratories posted an Intraday Rise of 5.24% in Regular Trading, trading at $332.19, with turnover of $118.0 million.

The clearest catalyst in recent news was another round of analyst target-price increases. JPMorgan raised its price target to $345 from $310 on October 14, after Morgan Stanley lifted its target to $340 from $300 on October 12, reinforcing positive sentiment toward the shares.

Background fundamentals also remain supportive. The company previously reaffirmed fiscal adjusted EPS guidance at the upper end of $11.15 to $11.45 and outlined a longer-term outlook for revenue CAGR of 5% to 7% through 2030, alongside low-double-digit compound annual EPS growth, strengthening the market view that earnings visibility and valuation recovery may continue.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment